focus -WSS

focus

author：leisure time 2025-09-14 14:46:27 - browse：292

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Lung cancer screening guidelines updated for cigarette smokers

entertainment

WSS

Medicare must police algorithms in Medicare Advantage, Dems say

Life sciences investors close nearly $6 billion in new funds

Key Senate panel to consider PBM, drug pricing reform package

Live blog: Hearing on CRISPR

Infant mortality in U.S. rose last year for first time in decades: CDC

Gene therapy’s promise and the high cost of hope

hotspot

focus

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Live blog: Hearing on CRISPR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Acelyrin, a rare IPO success, stumbles in its first big test

New air purifier tech could be key to improving indoor air quality

Life sciences investors close nearly $6 billion in new funds

State Dept. review finds Biden bears some blame for Afghanistan failures

Life sciences investors close nearly $6 billion in new funds

knowledge

Food makers to regulators: Ultra

Coloradans with cystic fibrosis could lose access to Trikafta

How housing is health care on Long Island

How to make the FDA’s new prescription one

Infant mortality in U.S. rose last year for first time in decades: CDC

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

focus

entertainment

hotspot